We are live on ! Find out more
AURA icon

Aura Biosciences

64 hedge funds and large institutions have $254M invested in Aura Biosciences in 2023 Q3 according to their latest regulatory filings, with 6 funds opening new positions, 26 increasing their positions, 19 reducing their positions, and 1 closing their positions.

New
Increased
Maintained
Reduced
Closed

500% more first-time investments, than exits

New positions opened: 6 | Existing positions closed: 1

50% more funds holding in top 10

Funds holding in top 10: 23 (+1)

37% more repeat investments, than reductions

Existing positions increased: 26 | Existing positions reduced: 19

8% more funds holding

Funds holding: 5964 (+5)

0.35% more ownership

Funds ownership: 71.6%71.95% (+0.35%)

24% less capital invested

Capital invested by funds: $334M → $254M (-$80.1M)

100% less call options, than puts

Call options by funds: $0 | Put options by funds: $9K

Holders
64
Holders Change
+5
Holders Change %
+8.47%
% of All Funds
1.02%
Holding in Top 10
3
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+50%
% of All Funds
0.05%
New
6
Increased
26
Reduced
19
Closed
1
Calls
Puts
$9K
Net Calls
-$9K
Net Calls Change
-$9K
Name Holding Trade Value Shares
Change
Change in
Stake
MCMC
1
Matrix Capital Management Company
New Hampshire
$48.1M
MVM
2
Medicxi Ventures Management
Jersey
$27.3M
EAM
3
Eventide Asset Management
Massachusetts
$27.1M +$962K +89,386 +3%
Adage Capital Partners
4
Adage Capital Partners
Massachusetts
$25.8M +$1.78M +165,000 +6%
Citadel Advisors
5
Citadel Advisors
Florida
$22.3M +$253K +23,486 +1%
DCMIC
6
Decheng Capital Management III (Cayman)
Cayman Islands
$18.2M +$9.36M +869,790 +297%
BlackRock
7
BlackRock
New York
$16.7M -$87.2K -8,106 -0.4%
Vanguard Group
8
Vanguard Group
Pennsylvania
$9.25M +$31.4K +2,922 +0.3%
Goldman Sachs
9
Goldman Sachs
New York
$8.91M -$363K -33,702 -3%
NCM
10
Nantahala Capital Management
Connecticut
$6.67M -$639K -59,433 -7%
RSCM
11
Rock Springs Capital Management
Maryland
$6.48M -$3.19M -296,861 -29%
T. Rowe Price Associates
12
T. Rowe Price Associates
Maryland
$5.89M -$91.4K -8,499 -1%
RCM
13
Regency Capital Management
Hawaii
$4.73M -$57.6K -5,355 -1%
Geode Capital Management
14
Geode Capital Management
Massachusetts
$4.72M +$289K +26,842 +5%
State Street
15
State Street
Massachusetts
$4.1M +$44K +4,093 +0.9%
Fidelity Investments
16
Fidelity Investments
Massachusetts
$3.22M -$807 -75 -0%
Northern Trust
17
Northern Trust
Illinois
$1.99M +$89.8K +8,351 +4%
LFCM
18
Long Focus Capital Management
Puerto Rico
$1.75M +$161K +15,000 +8%
Dimensional Fund Advisors
19
Dimensional Fund Advisors
Texas
$1M +$769K +71,520 +179%
TD Asset Management
20
TD Asset Management
Ontario, Canada
$968K +$580K +53,956 +100%
Citigroup
21
Citigroup
New York
$955K -$453K -42,070 -28%
Bank of New York Mellon
22
Bank of New York Mellon
New York
$752K +$12K +1,120 +1%
LCS
23
Levin Capital Strategies
New York
$727K +$119K +11,095 +16%
Charles Schwab
24
Charles Schwab
California
$652K
N
25
Nuveen
North Carolina
$539K

AURA Hedge Fund Activity: Q3 2023 in Review

64 of the 6,302 institutional investors tracked by Wall St. Rank reported a position in Aura Biosciences (AURA) for Q3 2023, worth a combined $254M — down 24% from $334M a quarter earlier.

Buyers outnumbered sellers: 6 funds opened new AURA positions and 1 closed out — a net gain of 5 holders — while 26 added to existing stakes and 19 trimmed.

The largest buyer was Decheng Capital Management III (Cayman), adding an estimated $9.36M. The largest seller was Bank of Montreal, exiting entirely with an estimated $5.21M sold.

  • 64 institutional investors held Aura Biosciences (AURA) as of Q3 2023, up from 59 in Q2 2023.
  • Funds reported $254M of Aura Biosciences stock for Q3 2023, down 24% quarter-over-quarter.
  • 6 funds opened new Aura Biosciences positions in Q3 2023 and 1 closed out, a net change of +5 holders.
  • The largest Aura Biosciences buyer in Q3 2023 was Decheng Capital Management III (Cayman), an estimated $9.36M added.
  • The largest Aura Biosciences seller in Q3 2023 was Bank of Montreal, an estimated $5.21M sold.

Based on aggregated 13F filings for Q3 2023.